In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Gregg Stone, MD, explains the details of the late-breaking RELIEVE-HF trial at ACC.24, where an inter-atrial shunt improved symptoms in HFrEF, but not in HFpEF patients.
Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli.
